Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05584241 · ClinicalTrials.gov registry record · NA
Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure
A NA study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by University of Michigan.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05584241: Active NA study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by University of Michigan.
NCT05584241 is a NA study of Alzheimer Disease and Mild Cognitive Impairment that is active but no longer recruiting, run by University of Michigan. The registered enrollment target is 100 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05584241, a NA study of Alzheimer Disease and Mild Cognitive Impairment, is active but no longer recruiting, sponsored by University of Michigan.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed project will assess long-term changes to health/lifestyle, advanced planning, and research engagement that Black and White patients with Amnestic Mild Cognitive Impairment (aMCI) make following disclosure of positron emission tomography-based amyloid and tau burden and associated risk of conversion to Dementia-Alzheimer's Type. Healthcare access will be explored as potential barrier to or facilitator of behavior change.
Primary Outcome
Subscale is a part of the Stages of Change Interview. Respondents will rate seven items relating to behavioral changes they have made post-disclosure on a Likert scale ranging from 1 = "I have not considered/am not interested in making this change" to 5 = "I have already made and maintained this change." Subscale score total ranges from 7 to 35 with higher scores indicating more engagement.
Conditions Studied
Interventions
- BEHAVIORAL Diagnostic Disclosure Protocol
- BEHAVIORAL Biomarker Disclosure Protocol
Study Locations (1)
Michigan
- The University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-02-20 |
| Est. Completion | 2026-05 |
| Phase | NA |
What the registry record for NCT05584241 still lists
NCT05584241 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Diagnostic Disclosure Protocol is the first listed.
NCT05584241 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05584241 about?
NCT05584241 is a clinical study titled "Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure". The proposed project will assess long-term changes to health/lifestyle, advanced planning, and research engagement that Black and White patients with Amnestic Mild Cognitive Impairment (aMCI) make following disclosure of positron emission tomography-based amyloid and tau burden and associated risk o...
What is the current status of trial NCT05584241?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2023-02-20. Estimated completion is 2026-05.
What conditions does trial NCT05584241 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder.
What interventions are being tested in trial NCT05584241?
The interventions under investigation include: Diagnostic Disclosure Protocol (BEHAVIORAL), Biomarker Disclosure Protocol (BEHAVIORAL).
Who is sponsoring clinical trial NCT05584241?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05584241 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05584241's enrollment target sits among peer trials
100 152nd of 306 higher than 151 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Brain Outcomes With Lifestyle Change in Down Syndrome
RECRUITING · NA
-
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
-
Connect-Home: Alzheimer's Disease and Related Dementias
RECRUITING · NA
-
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI